#1 Clinical Trials Search in Europe

Study on Flecainide and Amiodarone for Treating Atrial Fibrillation in Patients with Coronary Artery Disease and Ejection Fraction Over 35%

3 1 1 1

What is this study about?

This clinical trial is focused on studying the treatment of paroxysmal atrial fibrillation, a condition where the heart experiences irregular and often rapid beating. The study involves patients who have coronary artery disease but do not have ongoing heart muscle damage, and their heart’s pumping ability is above 35%. The trial compares two medications: flecainide acetate and amiodarone hydrochloride. Both are used to help restore a normal heart rhythm. Flecainide is being tested to see if it is more effective and just as safe as amiodarone in converting the heart to a normal rhythm in the emergency department setting.

The purpose of the study is to determine if flecainide is better than amiodarone in helping patients return to a normal heart rhythm. Participants will receive either flecainide or amiodarone through an injection. The study will monitor how well each medication works in restoring normal heart rhythm and how safe they are for the patients. The effects of the medications will be observed for up to 24 hours, with particular attention to any side effects or complications that may arise.

Throughout the study, the frequency of successful heart rhythm conversion and any side effects will be recorded. The trial aims to provide valuable information on the effectiveness and safety of these medications in treating paroxysmal atrial fibrillation in patients with coronary artery disease. This research could help improve treatment options for individuals experiencing this heart condition.

1 initial assessment

Upon arrival at the Emergency Department, an initial assessment is conducted to confirm eligibility for the trial. This includes verifying age, medical history, and current condition.

A 12-lead ECG is performed to document the presence of paroxysmal atrial fibrillation (AF).

2 consent and enrollment

After confirming eligibility, the patient is asked to sign an informed consent form to participate in the trial.

Once consent is obtained, the patient is officially enrolled in the study.

3 randomization and treatment allocation

The patient is randomly assigned to receive either flecainide acetate or amiodarone hydrochloride.

Both medications are administered as a solution for injection.

4 medication administration

The assigned medication is administered via injection in the Emergency Department.

The goal is to convert the heart rhythm from AF to a normal sinus rhythm.

5 monitoring and evaluation

The patient is monitored for up to 6 hours to assess the success of the cardioversion to sinus rhythm.

Monitoring includes checking for any side effects such as irregular heartbeats or changes in blood pressure.

6 follow-up and discharge

If the heart rhythm is successfully converted to sinus rhythm, the patient may be discharged from the Emergency Department.

Further monitoring may be conducted for up to 24 hours, including a 24-hour Holter monitor to track heart activity.

7 extended observation

The patient is observed for any adverse effects for up to 30 days following the administration of the medication.

This includes tracking any episodes of arrhythmias or other related symptoms.

Who Can Join the Study?

  • Age between 18 and 25 years old.
  • Have a condition called paroxysmal atrial fibrillation (AF), which is a type of irregular heartbeat. This must be confirmed by a test called a 12-lead ECG. The AF must have started less than 48 hours before arriving at the Emergency Department, or between 48 hours and 7 days with at least 30 days of blood-thinning medication.
  • Have a history of coronary artery disease without ongoing heart muscle damage. This can be shown by one of the following:
    • Had a procedure called angioplasty within the past year.
    • Had coronary artery bypass surgery within the last 3 years.
    • Had a negative result on a heart stress test using imaging within the past year, and also:
      • Had angioplasty more than a year ago, or
      • Had coronary artery bypass surgery more than 3 years ago, or
      • Has a history of a narrowing in the heart arteries greater than 60% without treatment to open them.
  • Have a left ventricular ejection fraction greater than 35%, which is a measure of how well the heart pumps blood. This must be confirmed by a heart ultrasound in the Emergency Department or within the last year.
  • Must sign a form agreeing to participate in the study, known as an informed consent form.

Who Cannot Join the Study?

  • Patients with a left ventricular ejection fraction of 35% or less cannot participate. This is a measure of how well the heart is pumping blood.
  • Patients with residual ischemia are excluded. This means there is still a lack of blood flow to the heart.
  • Patients who are not experiencing paroxysmal atrial fibrillation are not eligible. This is a type of irregular heartbeat that starts and stops suddenly.
  • Patients who are not in the Emergency Department for treatment are not eligible.
  • Patients who do not have coronary artery disease are excluded. This is a condition where the heart’s blood vessels are narrowed or blocked.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Kat Attica General Hospital Kifissia Greece

Other Sites

Site Name City Country Status
General Hospital Of Nea Ionia Konstantopouleio Patision Nea Ionia Greece
Hippokration Hospital Athens Greece

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Greece Greece
Not recruiting
13.04.2023

Trial locations

Investigated drugs:

Flecainide is a medication used to help restore a normal heart rhythm in people experiencing certain types of irregular heartbeats, such as paroxysmal atrial fibrillation. In this trial, flecainide is being tested to see if it is more effective than another medication in converting an irregular heartbeat back to a normal rhythm in patients who have heart disease but no ongoing heart muscle damage and a heart pumping ability above 35%.

Amiodarone is another medication used to treat and prevent a variety of irregular heartbeats. It works by helping to stabilize the heart’s rhythm. In this trial, amiodarone is being used as a comparison to see if flecainide is better at converting an irregular heartbeat to a normal rhythm in the same group of patients. The trial also aims to ensure that flecainide is at least as safe as amiodarone for these patients.

Investigated diseases:

Paroxysmal Atrial Fibrillation – This is a type of irregular heartbeat that starts and stops suddenly. It occurs when the heart’s upper chambers beat out of sync with the lower chambers. Episodes can last from a few minutes to several hours and may happen occasionally. During an episode, the heart may feel like it’s racing or fluttering. It can lead to symptoms such as palpitations, shortness of breath, and fatigue. The condition can be triggered by stress, alcohol, or caffeine, but often the cause is unknown.

Trial ID:
2024-519233-33-00
Protocol code:
FLECA-ED
NCT ID:
NCT05549752
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A Study of Intravenous Lidocaine to Reduce Inflammation in Patients Undergoing Heart Valve or Coronary Artery Bypass Surgery with Heart-Lung Machine

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of dapagliflozin and semaglutide to reverse prediabetes to normal blood sugar levels in patients with coronary artery disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark